PROGRAMME DE SOINS ET DE SUIVI DES PERSONNES GUÉRIES DE LA MVE EN RDC

2025-03-23





OVERVIEW



AT A GLANCE



- This dataset include 1139 unique individuals.
- Participants underwent a mean of 17.94 visits (min=1, max=44).
- Participants were followed for a mean duration of 2.14 years (min=0.03, max=4.52).




POPULATION CHARACTERISTICS

Characteristic	N = 1,139
Sex	
Female	627 (55%)
Male	512 (45%)
Age	29 (1 81)
Age group	
≤5 yrs	61 (5.4%)
5-15 yrs	135 (12%)
15-25 yrs	281 (25%)
25-45 yrs	457 (40%)
45-65 yrs	177 (16%)
>65 yrs	24 (2.1%)
occupation	
Agriculteur	315 (30%)
Autre	115 (11%)
Enfant	183 (18%)
Étudiant	45 (4.3%)
Femme au foyer	208 (20%)
Fonctionnaire d'Etat	14 (1.3%)
Minier	18 (1.7%)
Personne d'affaire	44 (4.2%)
Professeur/Universitaire	10 (1.0%)
Professionnel de santé	89 (8.5%)
n (%); Median (Min, Max)	

Sex and Age distribution

Number of participants over time Visits


Duration of follow up






COMORBIDITIES AND COMPLICATIONS

COMORBIDITIES



COMPLICATIONS






TECHNICAL NOTE




MISSINGNESS

Percent completeness





APPROACHES FOR MISSINGNESS





SCENARIOS




Figure 1

• For the downstream analyses, we proposed the **second scenario**.



CLINICAL EVALUATION



TRENDS

labels	6 months	12 months	18 months	24 months	36 months	Average	Improvement
Sensation grattage	6.43	0.00	0.00	0.00	15.18	4.32	-136.08
Murmures vesiculaires	65.62	70.89	63.86	60.71	42.41	60.70	35.37
Troubles sensitifs	100.00	0.00	0.00	0.00	0.00	20.00	100
Troubles equilibre coordination mouvements	100.00	100.00	100.00	100.00	0.00	80.00	100
Troubies sommeil	100.00	100.00	100.00	100.00	100.00	100.00	
Trouble langage	100.00	0.00	0.00	0.00	0.00	20.00	100
Flou visuel	0.00	0.00	0.00	0.00	7.85	1.57	-Inf
Abdomen sensible	0.00	0.00	0.00	0.00	6.81	1.36	-Inf


Clinical evolution of signs with a minimum prevalence of 10 cases and a minimum frequency of 5%.



CLINICAL EVALUATION AT BASELINE

Prevalence

Frequency




Baseline evaluation of signs with a minimum prevalence of 10 cases.



CLINICAL PRESENTATION OVER TIME

CLINICAL PRESENTATION WITHIN THE FIRST 9 MONTHS

Overall age ≤15 yrs age 15-25 yrs age 25-55 yrs age >55 yrs




Clinical signs with a minimum prevalence of 10 cases and a minimum frequency of 5%.



CLINICAL PRESENTATION WITHIN THE FIRST 3 YEARS

Overall age ≤15 yrs age 15-25 yrs age 25-55 yrs age >55 yrs



Clinical signs with a minimum prevalence of 10 cases and a minimum frequency of 5%.




PSYCHOLOGICAL EVALUATION



WITHIN THE FIRST 3 MONTHS

Started before EVD | Currently | Since last visit | Worsening since last visit




QUALITY OF LIFE (QALY)



At 6 months

At 12 months At 24 months At 36 months

Psychological evaluation at 6 months





DAY BY DAY PREVALENCE TRENDS

Prevalence

Number of individuals

Prevalence of clinical symptoms (months from ECT exit)





- -O- Flou visuel
- -O- Murmures vesiculaires
- -O- Photophobie vision
- -O- Rougeur oculaire
- -O- Sensation grattage
- -O- Sensibilite lumiere
- -O- Troubies sommeil
- Troubles equilibre coordination mouvements
- -O- Troubles sensitifs






DISEASE BURDEN



DISEASE BURDEN

At 12 months

At 24 months At 36 months





THANK YOU

